RxDoctor Payments Data

Shane Dunaway, MD

Family Medicine · Vancouver, WANPI 1174676423

Payments from drug & device makers

$285in general payments, 2019–2025

Across 12 payments — averaging $23.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$85
  • Exact Sciences$47
  • Dexcom, Inc.$34
  • Circassia Inc.$33
  • Merck$26
  • Boehringer Ingelheim$21
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie1$85
Exact Sciences2$47
Dexcom, Inc.2$34
Circassia Inc.2$33
Merck2$26
Boehringer Ingelheim1$21
Phadia US Inc.1$21
Medtronic1$18

How this compares

$285 in reported general payments places this provider in the 70th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$16,939
Medicare patients
146
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$119,287
EliquisApixaban60$82,046
XareltoRivaroxaban40$52,826
Invega SustennaPaliperidone Palmitate11$40,746
JanuviaSitagliptin Phosphate28$20,480
EntrestoSacubitril/Valsartan21$19,482
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,757
OzempicSemaglutide14$12,800
Spiriva HandihalerTiotropium Bromide17$10,846
Spiriva RespimatTiotropium Bromide15$10,820
Albuterol Sulfate HfaAlbuterol Sulfate310$8,171
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$8,124
Incruse ElliptaUmeclidinium Bromide15$8,085
Gabapentin242$7,469
Atrovent HfaIpratropium Bromide15$7,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$21$130,106105 claims
MerckJanuvia, Dulera$26$27,43046 claims
AbbVieLinzess$85$6,83713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Vancouver

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →